Inmode Stock News

InMode's products are part of the medical aesthetics industry that is expected to grow at an 11% CAGR over the next five years. Despite a punishing macro environment of late that has seen its share price decline over 80% from its peak, InMode has remained profitable while continuing to innovate. The strong new and second-hand sales market for their platforms suggest their customers continue to ...

InMode Ltd. (NASDAQ:INMD ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - Chief Executive Officer Michael Kreindel - Chief Technology Officer Yair Malca - Chief Financial Officer Eran Krieger - Medical Director and VP of Medical Affairs Rafael Lickerman - Vice President, Finance Conference Call Participants Matt Miksic -...

YOKNEAM, Israel, Oct. 30, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2024.

IRVINE, Calif. , Oct. 24, 2024 /PRNewswire/ -- InMode Ltd.

Expects Q3 Revenue Between $130.0 Million -$130.1 Million (including $31.9 Million in Revenue from First Half of 2024 Pre-orders), Decreases Full Year 2024 Guidance to $410 Million-$420 Million Conference call to be held on Wednesday, October 30, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 10, 2024 /PRNewswire/ -- InMode Ltd.

In September, thirty new analysts joined Seeking Alpha, offering diverse stock picks and insights, from Strong Buy to Strong Sell ratings. Highlighted picks include InMode Ltd., Intel Corporation, and iShares 20+ Year Treasury Bond ETF, each with unique investment theses and strong buy ratings. Analysts' backgrounds range from software engineering to finance, enhancing their stock research with...

YOKNEAM, Israel , Oct. 1, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies today announced the departure of Shakil Lakhani, President of North America effective September 30, 2024.

InMode's Q2 2024 revenue dropped by 36.5% year-over-year to $86.4 million, underlining macroeconomic challenges. The company revised its full-year 2024 revenue guidance to $430-$440 million due to slower platform rollouts and production delays. Lower interest rates from Federal Reserve cuts could boost demand for InMode's minimally invasive treatments, benefiting from reduced financing costs.